Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Becotatug - Shanghai Jinmante Biotechnology

Next Previous
Drug Profile

Becotatug - Shanghai Jinmante Biotechnology

Alternative Names: JMT-101

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yong Shun Technology Development
  • Developer CSPC ZhongQi Pharmaceutical Technology; Peking University; Shanghai Jinmante Biotechnology
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Colorectal cancer; Solid tumours
  • Phase I Oesophageal cancer

Most Recent Events

  • 25 Mar 2025 Shanghai JMT-Bio plans a phase II trial for Nasopharyngeal cancer (Metastatic disease, Second-line therapy and greater, Recurrent) in April 2025 (IV, Injection) (NCT06892431)
  • 23 Oct 2024 Phase-III clinical trials in Non-small cell lung cancer (Inoperable/Unresectable, Recurrent, Combination therapy, First-line therapy) in China (IV) (NCT06735391)
  • 26 Apr 2024 Becotatug is still in phase I trials for Non small cell lung cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top